Paper Details

  1. Home
  2. Paper Details

[Combination therapy with estramustine and docetaxel for hormone refractory prostate cancer].

Author: KannoToru, ShibasakiNoboru, TakeuchiHideo, TakiYoji, TsujiYutaka

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Combining Estramustine and Docetaxel proved effective in treating hormone-refractory prostate cancer, with a significant PSA reduction in most patients. However, further research is needed regarding optimal dosages and dosing regimens.
Paper Details　
Original Abstract of the Article :
Six patients with hormone refractory prostate cancer were orally administered 560 mg of Estramustine daily in 2 equally divided doses for four or five days. In addition 70 mg/m2 of Docetaxel was infused through intravenous drip from day 1, decreasing to 40-60 mg/m2 if any side effects such as bone m...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/15471069

データ提供：米国国立医学図書館（NLM）

Fighting Prostate Cancer: A Two-Pronged Approach

The world of oncology is constantly evolving, seeking new weapons to combat the relentless march of cancer. This study published in [Journal name], explores the effectiveness of a combination therapy using estramustine and docetaxel in treating hormone-refractory prostate cancer. The study focused on six patients, each receiving oral estramustine and intravenous docetaxel, with treatment continuing until disease progression or intolerable side effects.

A Combination Therapy Shows Promise

The results were encouraging, with a significant reduction in serum prostate specific antigen (PSA) levels observed in 83.3% of the patients. This suggests that this combined approach could be a viable treatment option for hormone-refractory prostate cancer. However, the study also highlighted the importance of monitoring for side effects, particularly bone marrow suppression. Further research is needed to optimize the dosage and dosing regimen for this therapy.

Navigating the Desert of Cancer Treatment

The fight against cancer is like navigating a vast and unforgiving desert. Finding the right treatment is like searching for an oasis, offering a chance for survival and recovery. While this study presents promising results, further research is crucial to ensure this combination therapy is both effective and safe for all patients.

Dr.Camel's Conclusion

The fight against prostate cancer is a journey through a challenging desert landscape. This study, like a welcome oasis, offers a glimmer of hope with its promising results from a combination therapy. However, as with any journey, further research is vital to ensure safe passage and ultimate victory over this disease.
Date :
  1. Date Completed 2004-12-02
  2. Date Revised 2018-11-30
Further Info :

Pubmed ID

15471069

DOI: Digital Object Identifier

15471069

Related Literature

Article Analysis
・Side Effects of estramustine
SNS
PICO Info
in preparation
Languages

Japanese

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.